Is WeGovy the Same Medication as Ozempic?

Have you been hearing all about WeGovy and Ozempic? Are you struggling to find the facts and separate the noise from the information? You are definitely not alone, and with all the different names and scientific explanations about these medications, it’s no wonder there’s confusion.

Many people wonder if WeGovy and Ozempic medications are the same or if there are any significant differences between them. That’s the reason that Bodyline wants to delve into the similarities and distinctions between WeGovy and Ozempic to provide you with a solid understanding of these injections. 

To answer the question of whether WeGovy is the same medication as Ozempic, the answer is yes, however there are some differences from the supplier that make both injectable treatments slightly different.

Marketing and Intentions

One of the primary differences between WeGovy and Ozempic lies in their marketing strategies and intended target audiences. 

Originally, Ozempic was developed and marketed as a treatment for individuals with type 2 diabetes. It was created to bring down blood sugar and to trigger the body to produce more insulin to aid in diabetes treatment. 

Then, throughout the medication’s studies, it was discovered that Ozempic had a significant positive impact on weight loss for individuals struggling with obesity. 

This outcome meant that the pharmaceutical manufacturer, Novo Nordisk, wanted to take the same medication and rebrand it as a new injectable pen called WeGovy to specifically target weight loss. Therefore, now Ozempic should be prescribed for the management of diabetes only and WeGovy for medical weight loss.

Contact Bodyline today to find out more about our safe and effective weight loss programmes and range of treatment options.

"*" indicates required fields

By submitting this form you agree to the Bodyline privacy policy.
This field is for validation purposes and should be left unchanged.

Active Ingredients and Mechanism of Action

Both WeGovy and Ozempic contain semaglutide as their active ingredient. 

Semaglutide is classified as a GLP-1 receptor agonist, which means it increases insulin secretion in the stomach lining and lowers glucagon secretion. This helps level out blood sugar and can improve health outcomes for those impacted by type 2 diabetes. 

Additionally, semaglutide affects the appetite centre of the brain, suppressing hunger pangs and cravings. This mechanism assists users in maintaining a caloric deficit, thereby increasing the likelihood of successful weight loss. When combined with a fully supported treatment plans, nutritional advice, and an active lifestyle, both WeGovy and Ozempic have shown incredible results.

One study saw semaglutide users lose on average 15% of their body weight and 14.4cm on waist circumference in a 68-week period. These weight loss results have been labelled game-changing for the treatment of obesity.

Bodyline offers weight loss injections including Wegovy, if suitable for the patient, as part of a supported medical weight loss programme, for those who struggle to lose weight with just diet and exercise alone. If you are considering using semaglutide for your weight loss journey, but don’t know whether it is right for you, be sure to get in touch with our specialist teams who will carry out a triage and take you through the weight loss options suitable for you.  Safe prescribing is Bodyline’s primary focus.

As a weight loss medication, WeGovy has the same active ingredient and mechanism of action as Ozempic.

Dosage Distinctions

While both medications contain the same active ingredient, there is a notable difference in their dosage. WeGovy is available in a higher dose than Ozempic, with a maximum dose of 2.4 mg, though this can be titrated to a dose that works best for the user based on side effects and results.   Alternatively, Ozempic’s maximum dose is 1.0 mg. 

The difference in dosage allows for more flexibility in treatment options and personalised approaches to weight loss. Therefore, WeGovy is not the same as Ozempic when it comes to the dose of semaglutide.

Administration and Convenience

Both WeGovy and Ozempic are administered once weekly via subcutaneous injection using slimming pens. If semaglutide or GLP-1 is prescribed for you, you will be taught how to inject yourself with the prefilled pen, administering the personalised dose of semaglutide. Therefore, WeGovy and Ozempic are administered the same way.

These pens provide a controlled dose that lasts throughout the week, effectively suppressing appetite and helping to regulate blood sugar levels. 

The ease of administration and the convenience of a weekly injection make these medications accessible and practical for individuals on a weight loss journey. 

Which Medication Works Better?

The question of which medical weight loss medication works better, ultimately depends on the patient. 

A consultation with one of our specialist nurses is crucial to determine the most suitable medication for your individual needs. We consider your medical history, weight loss goals, and your lifestyle before prescribing weight loss medications like WeGovy and Ozempic.

At Bodyline, we offer comprehensive medical wellness programs that incorporate a range of medication options as well as specialist clinical support for our patients on their weight loss journey. To learn more about our weight loss treatments and support, please contact us today.

Related blog posts

By now we should all have heard of the incredible weight loss results from GLP-1 receptor agonist medications and their ever-growing popularity. All over the UK, people are searching for access to ‘game changing’ medications to solve their weight problems. Searches for semaglutide, tirzepatide and liraglutide (brand names WeGovy/Ozempic, Mounjaro, and Saxenda respectively) have increased dramatically in the past year, and interest continues to rise. That’s because for the first time ever, there seems to be a potential long-term solution to the obesity epidemic that has afflicted the world over the past 30 years.
Despite the enormous popularity of WeGovy and its incredible impact on weight loss, a shortage of the injectable weight loss therapy has been ongoing in recent months. The semaglutide-containing injection has been dubbed “game-changing” for the treatment of obesity, and demand has been high, but manufacturer Novo Nordisk has struggled to keep up and has only released limited stock.
Mounjaro, also known as tirzepatide, is an innovative prescription medication that has shown great potential in promoting weight loss in clinical trials. Due to rising levels of obesity, and therefore increasing need for treatments, many people are rushing to try game-changing medications like Mounjaro to solve their problems.


Contact Bodyline to find out more how we can treat and support you to improve your health and wellbeing.

"*" indicates required fields

Select the Bodyline treatment that you would like to discuss*
By submitting this form you agree to the Bodyline privacy policy.